Pfizer (NYSE:PFE) received a $39.00 price objective from equities research analysts at BMO Capital Markets in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 5.61% from the company’s current price.
PFE has been the subject of several other research reports. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Barclays set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Thursday, October 26th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $38.12.
Pfizer (PFE) traded up $0.11 during mid-day trading on Wednesday, reaching $36.93. 17,720,000 shares of the company’s stock were exchanged, compared to its average volume of 16,890,000. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a one year low of $30.90 and a one year high of $37.37. The company has a market capitalization of $220,130.00, a PE ratio of 22.66, a price-to-earnings-growth ratio of 2.29 and a beta of 1.01.
Pfizer declared that its board has initiated a stock buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock valued at $1,065,220 in the last three months. Company insiders own 0.06% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. HL Financial Services LLC increased its holdings in shares of Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after buying an additional 35,744 shares in the last quarter. Hartford Financial Management Inc. grew its stake in shares of Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 835 shares during the last quarter. Cadence Bank NA grew its stake in shares of Pfizer by 1.4% during the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 1,428 shares during the last quarter. Majedie Asset Management Ltd grew its stake in shares of Pfizer by 7.9% during the second quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after purchasing an additional 24,531 shares during the last quarter. Finally, Stanley Laman Group Ltd. grew its stake in shares of Pfizer by 373.7% during the second quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after purchasing an additional 90,160 shares during the last quarter. 69.79% of the stock is owned by institutional investors.
WARNING: This article was originally published by American Market News and is owned by of American Market News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/24/bmo-capital-markets-analysts-give-pfizer-pfe-a-39-00-price-target-2.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
